Free shipping on all orders over $ 500


Cat. No. M2272
Suvorexant Structure


Size Price Availability Quantity
10mg USD 150 In stock
50mg USD 500 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

Suvorexant (MK-4305) is a dual orexin receptor antagonist currently under clinical investigation as a novel therapy for insomnia. Suvorexant is not currently approved for commercial use, but it has completed three Phase III trials. The recent FDA review showed that Suvorexant (MK-4305) is associated with increased somnolence the next day and users of higher doses had an increased rate of suicidal ideation. Suvorexant works by turning off wakefulness rather than by inducing sleep.

Cell Experiment
Cell lines
Preparation method
Incubation time
Animal Experiment
Animal models human OX 2 R expressed in transgenic rats
Formulation 25% hydroxypropyl- β -cyclodextrin
Dosages 0.1 – 2.0 mg/ kg
Administration i.v.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 450.92
Formula C23H23ClN6O2
CAS Number 1030377-33-3
Purity >99%
Solubility DMSO
Storage at -20°C

Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
Winrow CJ, et al. J Neurogenet. 2011 Mar;25(1-2):52-61. PMID: 21473737.

Related OX Receptor Products

MK-1064 is a potent, selective and orally active Orexin OX2 Receptor Antagonist for the research of insomnia.


SB-649868 is a selective orally active orexin (OX) receptor antagonist with pKi values of 9.4 and 9.5 at the OX1 and OX2 receptor, respectively.


SB-334867 is a selective non-peptide orexin OX1 receptor antagonist with a pKb value of 7.2.


TCS 1102 is a potent, dual orexin receptor antagonist (Ki values are 0.2 and 3 nM for OX2 and OX1 receptors respectively).


MK-3697 is an isonicotinamide small molecule, acting as a potent and selective Orexin 2 receptor antagonist with Ki = 0.95 nM.

Abmole Inhibitor Catalog 2017

Keywords: Suvorexant, MK-4305 supplier, OX Receptor, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.